Enrico Amo - DiaSorin SpA Non-Executive Director
| DSRLF Stock | USD 107.40 5.34 5.23% |
Director
Mr. Enrico Mario Amo has served as NonExecutive Director of Diasorin S.p.A. since March 26, 2007. He also serves as Member of the Audit Committee of the Company. He gained experience in auditing and consulting working at Arthur Andersen Co. E Ernst Whinney, as well as in corporate finance at Mediocredito Piemontese. From1985 to 1998, he worked at KPMG Consulting Corporationrationrate Finance. In 2002, he was appointed as General Manager of Investimenti e Partecipazioni SpA. Apart from that, he serves as Director at Finde SpA, IP Investimenti e Partecipazioni Srl, Industria Finanza SGR SpA, CID SpA, Corin Group PLC and 2IL Orthopaedics Limited. since 2007.
| Age | 60 |
| Tenure | 17 years |
| Phone | 39 01 614871 |
| Web | https://diasoringroup.com |
DiaSorin SpA Management Efficiency
The company has return on total asset (ROA) of 0.0902 % which means that it generated a profit of $0.0902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.198 %, meaning that it generated $0.198 on every $100 dollars invested by stockholders. DiaSorin SpA's management efficiency ratios could be used to measure how well DiaSorin SpA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kathleen LaPorte | Precipio | 55 | |
| Douglas Fisher | Precipio | 39 | |
| Mark Burnett | ProPhase Labs | 56 | |
| Michael Sherman | RadNet Inc | 74 | |
| Samuel Riccitelli | Precipio | 58 | |
| Cheryl Blanchard | Neuronetics | 53 | |
| David Swartz | RadNet Inc | 73 | |
| Jason Barr | ProPhase Labs | 36 | |
| Claudette Chan | Fonar | 86 | |
| Glenn Muir | Neuronetics | 59 | |
| Daniel Culver | Fonar | N/A | |
| Ronald Hunt | Neuronetics | 52 | |
| Robert Janoff | Fonar | 90 | |
| Charles OData | Fonar | 82 | |
| Christine Gordon | RadNet Inc | 61 | |
| Marvin Cadwell | RadNet Inc | 73 | |
| Louis Gleckel | ProPhase Labs | 60 | |
| Ronald Lehman | Fonar | 41 | |
| Mark Rimer | Precipio | 35 | |
| Stephen Campe | Neuronetics | 53 | |
| Julie Overton | bioAffinity Technologies Warran | N/A | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0902 |
DiaSorin SpA Leadership Team
Elected by the shareholders, the DiaSorin SpA's board of directors comprises two types of representatives: DiaSorin SpA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DiaSorin. The board's role is to monitor DiaSorin SpA's management team and ensure that shareholders' interests are well served. DiaSorin SpA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DiaSorin SpA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesca Pasinelli, Independent Director | ||
| Vittorio Squarotti, Non-Executive Director | ||
| Francesco Colotta, Senior Corporate Vice President and Chief Medical Officer | ||
| Riccardo Fava, Director of Investor Relations and Corporate Communication | ||
| Maria Landini, Non-Executive Director | ||
| Giuseppe Alessandria, Lead Independent Director | ||
| Roberta Somati, Independent Director | ||
| Antonio Boniolo, Non-Executive Director | ||
| Gustavo Denegri, Non-Executive Chairman of the Board | ||
| Carlo Rosa, CEO, General Manager and Executive Director | ||
| Fiorella Altruda, Independent Director | ||
| Monica Tardivo, Independent Director | ||
| John Eskdale, President DiaSorin Inc | ||
| Angelo Rago, Pres Corp | ||
| Pier Angelis, CFO, Sr. Corporate VP and Corporate Accounting Documents Officer | ||
| Ezio Garibaldi, Non-Executive Director | ||
| Michele Denegri, Non-Executive Vice Chairman of the Board | ||
| Giancarlo Boschetti, Non-Executive Director | ||
| Piergiorgio Pedron, Senior Corporate VP and CFO | ||
| Ulisse Spada, Mang Department | ||
| Tullia Todros, Independent Director | ||
| Stefano Ronchi, Sr. Corporate VP of HR | ||
| Eva Desana, Non-Executive Director | ||
| Enrico Amo, Non-Executive Director | ||
| Stefano Altara, Director | ||
| Franco Moscetti, Independent Director | ||
| Fabrizio Bonelli, Chief Officer | ||
| Ugo Gay, Sr Operations | ||
| Chen Even, Chief Commercial Officer and Executive Director |
DiaSorin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is DiaSorin SpA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0902 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 8.64 B | |||
| Shares Outstanding | 53.84 M | |||
| Shares Owned By Insiders | 57.50 % | |||
| Shares Owned By Institutions | 22.36 % | |||
| Price To Earning | 26.36 X | |||
| Price To Book | 4.73 X |
Pair Trading with DiaSorin SpA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaSorin SpA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaSorin SpA will appreciate offsetting losses from the drop in the long position's value.Moving against DiaSorin Pink Sheet
| 0.58 | TRCA | Twin Ridge Capital | PairCorr |
The ability to find closely correlated positions to DiaSorin SpA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaSorin SpA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaSorin SpA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaSorin SpA to buy it.
The correlation of DiaSorin SpA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaSorin SpA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaSorin SpA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaSorin SpA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaSorin SpA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for DiaSorin Pink Sheet analysis
When running DiaSorin SpA's price analysis, check to measure DiaSorin SpA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaSorin SpA is operating at the current time. Most of DiaSorin SpA's value examination focuses on studying past and present price action to predict the probability of DiaSorin SpA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaSorin SpA's price. Additionally, you may evaluate how the addition of DiaSorin SpA to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |